Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Gastroenterology Reports
Erschienen in: Current Gastroenterology Reports 4/2011

01.08.2011

The Role of Eosinophils and Mast Cells in Intestinal Functional Disease

verfasst von: Marjorie M. Walker, Alasdair Warwick, Chuin Ung, Nicholas J. Talley

Erschienen in: Current Gastroenterology Reports | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Functional gastrointestinal disorders (FGIDs) are common and currently defined by a symptom-based classification with no discernable pathology. In functional dyspepsia (FD), the duodenum is now implicated as a key area where symptoms originate.This is attributed to immune activation with increasing evidence indicating a role for duodenal eosinophilia. In irritable bowel syndrome (IBS), mastocytosis has been documented throughout the small and large intestine. Eosinophils and mast cells are an important link between innate and adaptive immunity, and are important in allergic type TH2 inflammation. Eosinophils may give rise to symptoms due to release of preformed cytokine proteins, which trigger neural excitation, muscle spasm, and pain. The close relationship of mast cells to nerves in IBS may similarly give rise to symptoms. Genetic studies also support of the role of innate immunity in FGIDs. The data supporting a prime role for eosinophils and mast cells in subsets of FD and IBS has become credible, and these data should be used to implement advances in diagnosis and therapeutic trials.
Literatur
1.
Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377–90.PubMedCrossRef
2.
Drossman DA. Functional GI disorders: what’s in a name? Gastroenterology. 2005;128:1771–2.PubMedCrossRef
3.
Kindt S, Van Oudenhove L, Broekaert D, et al. Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil. 2009;21:389–98.PubMedCrossRef
4.
•• Lee KJ, Tack J. Duodenal implications in the pathophysiology of functional dyspepsia. J Neurogastroenterol Motil. 2010; 16:251–7. An interesting paper highlighting the importance of the duodenum as the seat of symptoms in FD.PubMedCrossRef
5.
Hungin AP, Hill C, Raghunath A. Systematic review: frequency and reasons for consultation for gastro-oesophageal reflux disease and dyspepsia. Aliment Pharmacol Ther. 2009;30:331–42.PubMedCrossRef
6.
Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol. 2005;3:543–52.PubMedCrossRef
7.
Penston JG, Pounder RD. A survey of dyspepsia in Great Britain. Aliment Pharm Ther. 1996;10:83–9.CrossRef
8.
Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology. 2006;130:1466–79.PubMedCrossRef
9.
Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology. 2005;129:1756–80.PubMedCrossRef
10.
Talley NJ, Stanghellini V, Heading R, et al. Functional gastroduodenal disorders: a working team report for the Rome II consensus on functional gastrointestinal disorders. Gut. 1999;45 Suppl 2:II37–42.PubMedCrossRef
11.
Stanghellini V, Tosetti C, Paternico A, et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology. 1996;110:1036–42.PubMedCrossRef
12.
Sarnelli G, Caenepeel P, Geypens B, et al. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol. 2003;98:783–8.PubMedCrossRef
13.
Tack J, Caenepeel P, Fischler B, et al. Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology. 2001;121:526–35.PubMedCrossRef
14.
Friesen CA, Sandridge L, Andre L, et al. Mucosal eosinophilia and response to H1/H2 antagonist and cromolyn therapy in pediatric dyspepsia. Clin Pediatr (Phila). 2006;45:143–7.CrossRef
15.
• Talley NJ, Walker MM, Aro P, et al. Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol. 2007; 5:1175–83. The first study to implicate eosinophils in the duodenum in functional dyspepsia in adults.PubMedCrossRef
16.
Walker MM, Talley NJ, Prabhakar M, et al. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 2009;29:765–73.PubMedCrossRef
17.
Friesen CA, Andre L, Garola R, et al. Activated duodenal mucosal eosinophils in children with dyspepsia: a pilot transmission electron microscopic study. J Pediatr Gastroenterol Nutr. 2002;35:329–33.PubMedCrossRef
18.
• Friesen CA, Neilan NA, Schurman JV, et al. Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics. BMC Gastroenterol. 2009; 9:32. A study of treatment of functional dyspepsia in children relating this to pathophysiology.PubMedCrossRef
19.
Wallaert B, Desreumaux P, Coplin MC, et al. Immunoreactivity for interleukin 3 and 5 granulocyte/macrophage colony-stimulating factor of intestinal mucosa in bronchial asthma. J Exp Med. 1995;182:1897–904.PubMedCrossRef
20.
Pires GV, Souza HS, Elia CC, et al. Small bowel of patients with asthma and allergic rhinitis: absence of inflammation despite the presence of major cellular components of allergic inflammation. Allergy Asthma Proc. 2004;25:253–9.PubMed
21.
Powell N, Huntley B, Beech T, Knight W. Upper gastrointestinal symptoms and asthma: a manifestation of allergy? Gut. 2008;57:1026–7.PubMed
22.
Walker MM, Salehian SS, Murray CE, et al. Implications of eosinophilia in the normal duodenal biopsy—an association with allergy and functional dyspepsia. Aliment Pharmacol Ther. 2010;311:229–36.
23.
Futagami S, Shindo T, Kawagoe T, et al. Migration of Eosinophils and CCR2-/CD68-Double Positive cells into the duodenal mucosa of patients with postinfectious functional dyspepsia. Am J Gastroenterol. 2010;105:1835–42.PubMedCrossRef
24.
Friesen CA, Lin Z, Singh M, et al. Antral inflammatory cells, gastric emptying, and electrogastrography in pediatric functional dyspepsia. Dig Dis Sci. 2008;53:2634–40.PubMedCrossRef
25.
Hall W, Buckley M, Crotty P, et al. Gastric mucosal mast cells are increased in Helicobacter pylori-negative functional dyspepsia. Clin Gastroenterol Hepatol. 2003;1:363–9.PubMedCrossRef
26.
Nakajima S, Bamba N, Hattori T. Histological aspects and role of mast cells in Helicobacter pylori-infected gastritis. Aliment Pharmacol Ther. 2004;20 Suppl 1:165–70.PubMedCrossRef
27.
Li X, Chen H, Lu H, et al. The study on the role of inflammatory cells and mediators in post-infectious functional dyspepsia. Scand J Gastroenterol. 2010;45:573–81.PubMedCrossRef
28.
Schurman JV, Singh M, Singh V, et al. Symptoms and subtypes in pediatric functional dyspepsia: relation to mucosal inflammation and psychological functioning. J Pediatr Gastroenterol Nutr. 2010;51:298–303.PubMed
29.
Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480–91.PubMedCrossRef
30.
Saito YA, Schoenfeld P, Locke 3rd GR. The epidemiology of irritable bowel syndrome in North America: a systematic review. Aliment Pharmacol Ther. 2002;97:1910–5.
31.
Gwee KA. Post-infectious irritable bowel syndrome, an inflammation-immunological model with relevance for other IBS and functional dyspepsia. J Neurogastroenterol Motil. 2010;16:30–4.PubMedCrossRef
32.
Powell N, Huntley B, Beech T, et al. Increased prevalence of gastrointestinal symptoms in patients with allergic disease. Postgrad Med J. 2007;83:182–6.PubMedCrossRef
33.
Guilarte M, Santos J, de Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut. 2007;56:203–9.PubMedCrossRef
34.
Weston AP, Biddle WL, Bhatia PS, Miner Jr PB. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci. 1993;38:1590–5.PubMedCrossRef
35.
O’Sullivan M, Clayton N, Breslin NP, et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil. 2000;12:449–57.PubMedCrossRef
36.
Piche T, Saint-Paul MC, Dainese R, et al. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut. 2008;57:468–73.PubMedCrossRef
37.
Park JH, Rhee PL, Kim HS, et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2006;21:71–8.PubMedCrossRef
38.
Cremon C, Gargano L, Morselli-Labate AM, et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol. 2009;104:392–400.PubMedCrossRef
39.
Park JH, Rhee PL, Kim HS, et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2006;21:71–8.PubMedCrossRef
40.
Piche T, Saint-Paul MC, Dainese R, et al. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut. 2008;57:468–73.PubMedCrossRef
41.
Mahjoub FE, Farahmand F, Pourpak Z, et al. Mast cell gastritis: children complaining of chronic abdominal pain with histologically normal gastric mucosal biopsies except for increase in mast cells, proposing a new entity. Diagn Pathol. 2009;4:34.PubMedCrossRef
42.
Taylor TJ, Youssef NN, Shankar R, et al. The association of mast cells and serotonin in children with chronic abdominal pain of unknown etiology. BMC Res Notes. 2010;3:265.PubMedCrossRef
43.
•• Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009; 136:1979–88. An excellent review of this condition.PubMedCrossRef
44.
Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut. 2004;53:1096–101.PubMedCrossRef
45.
Bercík P, Wang L, Verdú EF, et al. Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction. Gastroenterology. 2004;127:179–87.PubMedCrossRef
46.
Barbara G, Vallance BA, Collins SM. Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice. Gastroenterology. 1997;113:1224–32.PubMedCrossRef
47.
Motomura Y, Khan WI, El-Sharkawy RT, et al. Mechanisms underlying gut dysfunction in a murine model of chronic parasitic infection. Am J Physiol Gastrointest Liver Physiol. 2010;299:G1354–60.PubMedCrossRef
48.
Arisawa T, Arisawa S, Yokoi T, et al. Endoscopic and histological features of the large intestine in patients with atopic dermatitis. J Clin Biochem Nutr. 2007;40:24–30.PubMedCrossRef
49.
De Giorgio R, Barbara G. Is irritable bowel syndrome an inflammatory disorder. Curr Gastroenterol Rep. 2008;10:385–90.PubMedCrossRef
50.
• Spencer LA, Weller PF. Eosinophils and Th2 immunity: contemporary insights. Immunol Cell Biol. 2010; 88:250–6. A good review of this subject.PubMedCrossRef
51.
• Galli SJ, Tsai M. Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. Eur J Immunol. 2010; 40:1843–51. A good review of this subject.PubMedCrossRef
52.
Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693–702.PubMedCrossRef
53.
Buhner S, Li Q, Vignali S, et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology. 2009;137:1425–34.PubMedCrossRef
54.
Simon D, Wardlaw A, Rothenberg ME. Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract. J Allergy Clin Immunol. 2010;126:3–13.PubMedCrossRef
55.
Powell N, Walker MM, Talley NJ. Gastrointestinal eosinophils in health, disease and functional disorders. Nat Rev Gastroenterol Hepatol. 2010;7:146–56.PubMedCrossRef
56.
Abreu MT, Fukata M, Arditi M. TLR signaling in the gut in health and disease. J Immunol. 2005;174:4453–60.PubMed
57.
Nagase H, Okugawa S, Ota Y, et al. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J Immunol. 2003;171:3977–82.PubMed
58.
Brint EK, MacSharry J, Fanning A, et al. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2010 Nov 23. [Epub ahead of print].
59.
• Villani AC, Lemire M, Thabane M, et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology. 2010; 138:1502–13. A well conducted study from this group, who have published good studies from this cohort of patients.PubMedCrossRef
60.
McKernan DP, Nolan A, Brint EK, et al. Toll-like receptor mRNA expression is selectively increased in the colonic mucosa of two animal models relevant to irritable bowel syndrome. PLoS ONE. 2009;4:e8226.PubMedCrossRef
61.
Tkaczyk C, Jensen BM, Iwaki S, et al. Adaptive and innate immune reactions regulating mast cell activation: from receptor-mediated signaling to responses. Immunol Allergy Clin North Am. 2006;26:427–50.PubMedCrossRef
62.
•• Bischoff SC. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol. 2007; 7:93–104. An excellent review.PubMedCrossRef
63.
Varadaradjalou S, Féger F, Thieblemont N, et al. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol. 2003;33:899–906.PubMedCrossRef
64.
Mrabet-Dahbi S, Metz M, Dudeck A, et al. Murine mast cells secrete a unique profile of cytokines and prostaglandins in response to distinct TLR2 ligands. Exp Dermatol. 2009;18:437–44.PubMedCrossRef
65.
Dietrich N, Rohde M, Geffers R, et al. Mast cells elicit proinflammatory but not type I interferon responses upon activation of TLRs by bacteria. PNAS. 2010;107:8748–53.PubMedCrossRef
66.
Navarini AA, Recher M, Lang KS, et al. Increased susceptibility to bacterial superinfection as a consequence of innate antiviral responses. Proc Natl Acad Sci USA. 2006;103:15535–9.PubMedCrossRef
67.
Auerbuch V, Brockstedt DG, Meyer-Morse N, et al. Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J Exp Med. 2004;200:527–33.PubMedCrossRef
68.
Shahangian A, Chow EK, Tian X, et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest. 2009;119:1910–20.PubMedCrossRef
69.
O’Connell RM, Saha SK, Vaidya SA, et al. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J Exp Med. 2004;200:437–45.PubMedCrossRef
70.
Carrero JA, Calderon B, Unanue ER. Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection. J Exp Med. 2004;200:535–40.PubMedCrossRef
71.
Kasakura K, Takahashi K, Aizawa T, et al. A TLR2 ligand suppresses allergic inflammatory reactions by acting directly on mast cells. Int Arch Allergy Immunol. 2009;150:359–69.PubMedCrossRef
72.
O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:41–551.
73.
Brenner D, Moeller M, Chey W, et al. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009;104:1033–49.PubMedCrossRef
74.
McCurdy JD, Olynych TJ, Maher LH, et al. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J Immunol. 2003;170:1625–9.PubMed
75.
Yang H, Wei J, Zhang H, et al. Upregulation of Toll-like Receptor (TLR) expression and release of cytokines from mast cells by IL-12. Cell Physiol Biochem. 2010;26:337–46.PubMedCrossRef
76.
Yang H, Wei J, Zhang H, et al. Upregulation of Toll-like receptor (TLR) expression and release of cytokines from P815 mast cells by GM-CSF. BMC Cell Biol. 2009;10:37.PubMedCrossRef
77.
Tancowny BP, Karpov V, Schleimer RP, et al. Substance P primes lipoteichoic acid- and Pam3CysSerLys4-mediated activation of human mast cells by up-regulating Toll-like receptor 2. Immunology. 2010;131:220–30.PubMedCrossRef
78.
Akbar A, Yiangou Y, Facer P, et al. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut. 2008;57:923–9.PubMedCrossRef
79.
Tahara T, Shibata T, Wang F, et al. Genetic polymorphisms of molecules associated with innate immune responses, TRL2 and MBL2 genes in Japanese subjects with functional dyspepsia. J Clin Biochem Nutr. 2010;47:217–23.PubMedCrossRef
80.
Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol. 1999;73:329–68.PubMedCrossRef
81.
Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709–60. 85.PubMedCrossRef
82.
Holtkamp W, Stollberg T, Reis HE. Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease. J Clin Gastroenterol. 1995;20:123–6.PubMedCrossRef
83.
• Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007; 132:913–20. A good study looking at immune activation and inflammation in IBS.PubMedCrossRef
84.
Anderson AE, Worku ML, Khamri W, et al. TLR9 polymorphisms determine murine lymphocyte responses to Helicobacter: results from a genome-wide scan. Eur J Immunol. 2007;37:1548–61.PubMedCrossRef
85.
Pironti A, Tadeu V, Pedroni A, et al. Role of routine small intestinal biopsy in adult patient with irritable bowel syndrome-like symptoms. Minerva Med. 2010;101:129–34.PubMed
86.
Chey WD, Nojkov B, Rubenstein JH, et al. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol. 2010;105:859–65.PubMedCrossRef
87.
Khan S, Chang L. Diagnosis and management of IBS. Nat Rev Gastroenterol Hepatol. 2010;7:565–81.PubMedCrossRef
Metadaten
Titel
The Role of Eosinophils and Mast Cells in Intestinal Functional Disease
verfasst von
Marjorie M. Walker
Alasdair Warwick
Chuin Ung
Nicholas J. Talley
Publikationsdatum
01.08.2011
Verlag
Current Science Inc.
Erschienen in
Current Gastroenterology Reports / Ausgabe 4/2011
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-011-0197-5

Weitere Artikel der Ausgabe 4/2011

Current Gastroenterology Reports 4/2011 Zur Ausgabe

ReviewPaper

Carbohydrate Provision in the Era of Tight Glucose Control

ReviewPaper

Mechanisms Underlying Visceral Hypersensitivity in Irritable Bowel Syndrome

ReviewPaper

Current Trends in Critical Care Nutrition

ReviewPaper

Current Perception of Nutrition Education in U.S. Medical Schools

Clinical Trial Report

Helicobacter pylori: Is it a Complete Villain?

ReviewPaper

Acute Pancreatitis: Should We Use Antibiotics?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise